. 2020 Apr 25;99(7):3481–3486. doi: 10.1016/j.psj.2020.03.049

Table 2.

In vitro viability assays evaluating selected concentrations of DCA for antihistomonal properties.¹

Assay 1	Viable cells/mL (Log₁₀)
Treatment	After 7–8.5 h incubation
PBS	6.22 ± 0.02^a
0.4 mM DCA	6.25 ± 0.03^a
2 mM DCA	0.00 ± 0.00^b
4 mM DCA	0.00 ± 0.00^b
Assay 2
Treatment	After 6–8 h incubation
PBS	6.11 ± 0.02^a
0.5 mM DCA	6.12 ± 0.05^a
1 mM DCA	4.71 ± 0.25^b
2 mM DCA	0.00 ± 0.00^b
4 mM DCA	0.00 ± 0.00^b
Assay 3
Treatment	After 4–6 h incubation	After 27–29 h incubation
PBS	6.30 ± 0.05^a	6.48 ± 0.01^a
0.5 mM DCA	6.31 ± 0.03^a	6.18 ± 0.07^b
1 mM DCA	6.16 ± 0.04^b	4.46 ± 1.25^c
2 mM DCA	1.34 ± 0.92^c	0.00 ± 0.00^c

^a–cData are expressed as mean ± SEM, n = 5 samples. Statistical evaluation using ANOVA followed by Tukey's multiple post hoc test. Means with no common superscript differ significantly (P ≤ 0.05).

Abbreviation: DCA, deoxycholic acid.

Assays 1–3 began with concentrations of 2.01 × 10⁶, 6.88 × 10⁵, and 6.35 × 10⁵ cells/mL of the wild-type Histomonas meleagridis, respectively, added at a ratio of 100 μL cells:50 μL treatment and incubated under anaerobic conditions at 40°C.